Annual sales fell from KRW 5.67 billion in 2022 to KRW 2.7 billion in 2023, a 52.4% decline, then rose to KRW 30.1 billion in 2024 (up 1,016.8%) and KRW 32 billion in 2025 (up 6.3%). Sales increased in 2024 and 2025, and 2025 was the largest year of 2022 to 2025.
The 2024 jump coincides with the March 2024 absorption of Dongin Biotech, so the figure likely includes merger effects.
Operating results moved from an operating loss of KRW 7.61 billion in 2022 and KRW 7.33 billion in 2023 to an operating profit of KRW 988 million in 2024, then back to an operating loss of KRW 2.85 billion in 2025. Operating margin went from -134.2% in 2022 and -271.6% in 2023 to 3.3% in 2024 and -8.9% in 2025.
The company attributed the 2025 operating loss to higher costs from the weaker won, development expenses and higher selling and administrative expenses.
Net loss attributable to controlling shareholders was KRW 12.8 billion in 2022, KRW 9.23 billion in 2023, KRW 161 million in 2024 and KRW 3.93 billion in 2025, so the company posted losses in each of these four years.
The 2025 consolidated net loss included a higher income tax expense from reviewing deferred tax assets, which the company described as a non-cash charge. Operating cash flow was KRW 1.37 billion positive in 2022, then negative in each year from 2023 to 2025, reaching minus KRW 5.97 billion in 2025.
Quarterly sales went from KRW 7.7 billion in 2025 Q3 to KRW 7 billion in Q4 (down 9.0% quarter on quarter), bottomed at KRW 5.91 billion in 2026 Q1 (down 15.6%), then rose to KRW 6.31 billion in Q2 and KRW 8.47 billion in Q3.
Operating losses widened from KRW 1.05 billion in 2025 Q3 to KRW 1.73 billion in 2026 Q1, then narrowed to KRW 1.52 billion in Q2 and KRW 781 million in Q3. The controlling-shareholder net loss peaked at KRW 2.86 billion in 2026 Q2 and was KRW 869 million in Q3, with KRW 8 billion of losses over the last four quarters.
Whether the Q3 margin improvement came from gross margin or from cost control will become clearer in the 2026 annual report's cost structure. The debt ratio fell from 9,076.0% in 2023 to 51.0% in 2024 and 82.1% in 2025, with equity of KRW 24.3 billion and total liabilities of KRW 19.9 billion at year-end 2025.